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Table 1. Viral infections
Viral infections ADV EBV CMV BKV HHV-6
Prevalance 66/124 (53%) 47/124 (38%) 25/124 (20%) 26/48 (54%) 23/77 (30%)
Viremia only (n) 16 35 16 1 7
Disseminated disease (n) 29 9 8 14 4
Reduced-intensity conditioning 39/60 (65%) 19/60 (32%) 13/60 (22%) 7/20 (35%) 14/40 (35%)
Myeloablative conditioning
With ATG 26/55 (47%) 26/55 (47%) 12/55 (22%) 19/26 (73%) 8/32 (25%)
Without ATG 1/9 (11%) 2/9 (22%) 0 (0%) 0/2 (0%) 1/5 (20%)
Fanconi anemia (T-cell depleted) 5/14 (36%) 4/14 (29%) 4/14 (29%) 6/9 (67%) 2/7 (29%)
Median post-HSCT day
of viral detection (range)
26 (0-341) 42 (4-763) 15 (0-78) 36 (13-119) 86 (1-419)
Viremia was defined as the presence of virus in blood. Disseminated infection was defined as virus detection in at least two different organ systems.
N: patients with a specified condition, (%) percentage of patients affected. Myeloablative conditioning regimen: Busulfan/Cyclophosphamide/Anti-
thymocyte Globulin (ATG) or Cyclophosphamide/TBI. Reduced-intensity conditioning regimen:Alemtuzumab/Fludarabine/Melphalan
S316 Poster Session Ireceived a reduced-intensity conditioning (RIC) regimen, 14 Fan-
coni anemia patients received RIC regimen with T-cell depletion
of the graft. All patients were monitored for cytomegalovirus
(CMV), Epstein-Barr virus (EBV), adenovirus (ADV) weekly in
blood by PCR testing until day +100. Human Herpes Virus-6
(HHV-6) and BK virus (BKV) were monitored when clinically indi-
cated. Viral infection is defined a quantitative PCR detection in
blood or qualitative detection in stool, urine, body fluids or relevant
tissue.
Results: Table 1 demonstrates the prevalence and features of most
common viral infections. Overall survival was 70% with viral infec-
tion as the cause of death in 12 patients (10%).
Discussion:Adenovirus and BK virus were themost prevalent infec-
tions, detected in half of the transplant patients with adenovirusmost
likely to be disseminated. The use of Alemtuzumab, ATG and T-cell
depletion is associated with increased risk of viral infection. We ob-
served a higher prevalence of Adenovirus infections compared to
other reports, likely due to high percentage of unrelated donors
and use of Alemtuzumab and ATG in these patients. Our data rein-
force the importance of ADV as a potential pathogen causing a high
rate of disseminated infection in transplant recipients.298
ROMIPLOSTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR
CELL TRANSPLANTATION: RESULTS OF A PILOT STUDY
Voloshin, S.V., Schmidt, A.V., Shuvaev, V.A., Fominykh, M.S.,
Abdulkadyrov, K.M. Russian Research Institute of Haematology and
Transfusiology, Saint-Petersburg, Russian Federation
Introduction: A number of studies have demonstrated that G-CSF
can fasten neutrophil recovery in patients undergoing high-dose che-
motherapy (HDT) and transplantation of autologous peripheral
blood progenitor cells (PBPCT). However, the only measure to cor-
rect post-transplant thrombocytopenia is still donor platelets trans-
fusions. Recently, immune thrombocytopenic purpura management
has changed with introduction of thrombopoietin receptor agonists
(TRA), which were highly effective and safe in such patients. To
date, the only two TRA are available – romiplostim and eltrombo-
pag. It is possible that administration of TRA can significantly alter
clinical course of patients undergoing HDT. To address this ques-
tion, we initiated a pilot study to assess the efficacy of TRA after
HDT with PBPCT.
Patients and Methods: Seven patients (median age, 45 years; range
21-56; 6male and 1 female) suffered from non-Hodgkin’s lymphoma
(n5 2), Hodgkin’s lymphoma (n5 2) and multiple myeloma (n5 3)
were treated with HDT and PBPCTwith romiplostim support. Ro-
miplostimwas given subcutaneously at a dose of 250 mg on day of au-
tologous PBPC reinfusion. Twelve patients (median age, 39 years;
range 19-64; 6 male and 6 female) with NHL (n 5 6), HD (n 5 5)
and MM (n 5 1) were enrolled in the control group (without romi-
plostim). The end points of this study were the times of plateletsrecovery (TPR), the duration of thrombocytopenia, and the duration
of hospitalization.
Statistical analysis: Variable comparisons were evaluated by non-
parametric statistical methods (Mann-Whithey U test for continu-
ous variables and Fisher exact and Chi-square tests for categorical
variables).
Results:The duration of thrombocytopenia grade III was 10.7 days
in the romiplostim and 19.0 days in the control group (p 5 0.044).
The duration of thrombocytopenia grade IV was 6.9 and 13.8 days
in average groups, resp. (p 5 0.259). TPR grade III was 13.9 days
for romiplostim group and 22.2 days for control group (p 5
0.044). TPR grade IV was 13.0 and 18.7 days according to study
groups (p 5 0.035). The duration of hospitalization was 27.9 in
the romiplostim and 36.7 days in the control group (p 5 0.021).
Conclusion: This study demonstrates a tendency that the duration
of thrombocytopenia and hospital stay, the times of platelet recovery
are shortened when romiplostim is administered after HDT and
PBPCT. It seems highly likely that the use of romiplostim in setting
of autologous transplants improves clinical course of patients under-
going HDT.299
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Background: Double stranded DNA viruses (dsDNA) viral infec-
tions continue to be a significant cause of morbidity andmortality af-
ter allogeneic hematopoietic stem cell transplantation (HSCT).
These include cytomegalovirus (CMV), Epstein-Barr virus (EBV),
Adenovirus (ADV), Human Herpes Virus-6 (HHV-6) and BK virus
(BK). Currently available antiviral therapy has variable efficacy and,
more importantly, is associated with significant hematologic and re-
nal toxicities. CMX001, an orally bioavailable lipid conjugate of ci-
dofovir, is under investigation for the prevention and treatment of
these dsDNA viruses. Clinical data concerning the use of CMX001
for treatment of ADV andCMVhave been reported. However, there
is limited information available on the use of CMX001 prior to en-
graftment in allogeneic HSCT recipients.
Methods:We report on 4 patients with dsDNA viruses treated with
CMX001 prior to engraftment after allogeneic HSCT. The median
age was 2.1 years (Range 0.5 to 9.8). The preparative regimen con-
sisted of Alemtuzumab, Fludarabine andMelaphalan for all patients.
All patients had received first-line antiviral therapy (Ganciclovir, Fo-
scarnet or Cidofvoir) before starting on CMX001. Virologic re-
sponse (VR) was defined as 99% drop from baseline or
Table 1. Patient Characteristics
Patient Diagnosis
Donor
Source Virus
Days of
CMX001
treatment
Neutrophil
Engraftment Dose of CMX001 % Donor Engraftment
1 SCID MUD ADV +11 to +54 +13 4 mg/kg/dose BIW 100
2 MDS with
Monosomy 7
MSD CMV +2 to +39 +11 4 mg/kg/dose BIW for 6 doses then 2 mg/kg/
dose BIW x 4 doses
100
3 Autoimmune
neutropenia
and Hepatitis
MUD CMV +3 to +30 +13 4 mg/kg/dose BIW x 7 doses then 4 mg/kg/dose
QW for 1 dose
0
4 XLP MUD HHV6 -48 to +7 +11 2 mg/kg/dose BIW 100
SCID: Severe Combined Immunodeficiency; MDS: Myelodysplastic Syndrome; XLP: X-Linked Lymphoproliferative Disorder; HHV6: Human Herpes
Virus -6; Neutrophil Engraftment: Day post HSCTANC > 500; BIW: twice a week; QW: weekly.
Poster Session I S317undetectable viral DNA in blood. Patient characteristics are shown
in Table 1.
Results:No hematologic toxicity from CMX001 was observed with
prompt neutrophil engraftment in all patients. The patient with au-
tologous recovery was considered to be at very high risk for graft re-
jection secondary to his diagnosis. No adverse events attributable to
CMX001 were seen with either the 4 mg/kg/dose or 2 mg/kg/dose
twice weekly dosing. Three of four patients had a. 1 log drop in vi-
ral load at the end of 1 week of therapy. VR was seen in 3/4 patients
with amedian time to achieve VR of 2 weeks (range 1-3). The patient
who did not have a VR had a.75% decrease in viral load by the end
of week 1 of treatment that was sustained throughout the 6 weeks of
CMX001 treatment.
Discussion: Though a small number of patients were treated, a fa-
vorable safety profile was observed in these patients with no evidence
of delayed hematologic engraftment attributed to CMX001. Four
patients received doses exceeding those currently being studied.
CMX001 is a promising therapy for potential use prior to engraft-
ment in HSCT recipients. Further investigation to confirm the
safety of CMX001 prior to engraftment in HSCT recipients is war-
ranted.300
DISCERNING POST HSCT IMMUNE RESPONSE TO THE INFLUENZA VAC-
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Influenza infections following hematopoietic stem cell transplan-
tation (HSCT) are potentially life threatening.While newer antiviral
medications may reduce influenza morbidity, the ideal preventative
strategy is unknown in post-HSCT patients. Prior studies demon-
strate that a single influenza vaccine is relatively ineffective at induc-
ing influenza specific immunity, especially early after HSCT. We
hypothesized that a second vaccine dose, as is standard of care in vac-
cine na€ıve pediatric patients, might improve vaccine efficacy post-
HSCT. During the 2010 influenza season, we conducted a clinical
trial with patients who were.60 days post HSCT, and randomized
them to receive either 1 (n5 30) or 2 (n5 32) flu vaccines separated
by one month. Blood samples were obtained pre-vaccination, 4
weeks and 8 weeks after the first vaccine for hemagglutination and
IFN-g ELISPOT testing. Of the 62 patients, 45 were.18 yrs, 24 re-
ceived non-myeloablative conditioning and 22 were umbilical cord
blood transplant recipients. Hemagglutination responses to the
2010/2011 vaccine components (H3N2, H1N1 and B/Victoria)
were significantly greater for patients vaccinated$1 year post trans-
plant (p\5 0.005 for all 3 strains) compared to those vaccinated at
earlier time points. Testing of T cell specific responses is ongoing,
but week 8 ELISPOT samples show that 7/15 tested patient samples
had IFN-g vaccine specific responses (defined as.10x increase over
baseline). Interestingly, we observed influenza specific T cell re-
sponses in patients without recognizable antibody responses
(n 5 4/15). Vaccine specific T cell responses were observed in 2/8
patients\1 yr post-HSCT and 5/7 .1 yr post-HSCT. Recipientsof 2 vaccines did not show a significant improvement in hemaggluti-
nation responses. This study shows that in some cases vaccinating
before the recommended 6 months post HSCT may be beneficial
sinceT cell responses can be induced. Analysis is ongoing with hopes
to delineate T cell vaccine response relationships between the two
cohorts and the various stem cell sources.301
PULMONARY FUNCTION (PF) AFTER STEM CELL TRANSPLANT (SCT) IS
SIGNIFICANTLY BETTER IN CHILDREN AND ADOLESCENTS WHO RE-
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WHO DEVELOP CHRONIC GVHD (CGVHD)
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Radhakrishnan, K.1, Harrison, L.3, Cairo, M.S.3 1Columbia University,
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Background: Deterioration in PF after MAC and SCT has previ-
ously been reported in pediatric recipients (Fanfulla et al., ERJ,
1997). RTC has been associated with decreased systemic complica-
tions following SCT (Satwani/Cairo, BBMT, 2005).
Objectives: To determine in a multivariate analysis the risk factors
associated with PF deterioration in pediatric recipients following
SCT.
Design/Method: All patients who underwent SCT under IRB ap-
proved studies were analyzed for PF by standard methods. Reliable
spirometry results pre-SCT and 1-2 years post-SCT were analyzed
on forty recipients, lung volume on twenty-six patients, and diffusion
capacity on thirty-five patients. Pre and post-SCT results were com-
pared using paired t-test analysis. Univariate sub-group analysis was
carried out using the unpaired t-test on the post-SCT results to de-
termine which variables contribute to PF deterioration. All variables
with a p-value less than 0.2 in univariate analysis were included in
a multivariate regression analysis.
Results:M/F 27/13, median age 13 years (5 to 21), malignant/non-
malignant 26/14, and RTC/MAC 26/14. Forced Vital Capacity
(FVC), Forced Expiratory Volume in 1-second (FEV1), Total
LungCapacity (TLC), andDiffusion Capacity (DLCO) were all sig-
nificantly reduced after transplant (Table 1). FEV1/FVC values were
not significantly different before and after SCT.
Sub-group analysis revealed worse PF in patients who underwent
MAC (FVC 71.36 5.3%, FEV1 72.76 4.8%, TLC 74.96 6.4%) as
compared with those who underwent RTC (FVC 80.4 6 2.6%,
FEV1 83.2 6 3.5%, TLC 90.4 6 4.0%) (p 5 0.045, 0.044, and
0.021 respectively). Additionally, patients with cGVHD had signifi-
cantly reduced FVC (68.1 6 4.3% v 81.1 6 2.9%, p 5 0.009) and
FEV1 (72.26 5.6% v 82.66 3.3%, p5 0.05) when compared to pa-
tients without cGVHD.
In multivariate logistic regression, undergoing RTC vs MAC was
an independent, significant predictor of greater post-SCT TLC
(p5 0.046). Additionally, development of cGVHD was an indepen-
dent, significant predictor for reduced FVC post-transplant
(p 5 0.047).
